Want to see IBRX full AI Analyst Report?
IBRX Stock Chart & Stats
$7.10
-$0.30(-4.05%)
At close: 4:00 PM EDT
$7.10
-$0.30(-4.05%)
Day’s Range― - ―
52-Week Range$1.95 - $12.43
Previous CloseN/A
Volume8.52M
Average Volume (3M)11.35M
Market Cap
$8.10B
Enterprise Value$8.62K
Total Cash (Recent Filing)$357.37M
Total Debt (Recent Filing)$38.71M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Nov 05, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding1,059,836,300
10 Day Avg. Volume8,016,374
30 Day Avg. Volume11,347,191
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)-3.65
Price to Sales (P/S)16.08
P/FCF Ratio-5.90
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$13.00Price Target Upside83.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.84
Revenue Forecast (FY)$222.44M
Bulls Say, Bears Say
Bulls Say
Commercial TractionSustained quarter-to-quarter product revenue growth and record net product sales indicate durable physician adoption of ANKTIVA and an increasingly routinized commercial model. Repeated sequential growth supports scalable recurring revenues, improves visibility for commercial investment, and strengthens long-term revenue base for clinical programs.
Very High Gross MarginsA ~94% gross margin is structurally advantageous for profitability as revenue scales: it allows incremental sales to flow strongly to the operating line once fixed commercial and R&D costs stabilize. High product-level margins support durable cash generation potential per unit of sales and pricing flexibility in markets.
Regulatory & Supply ExpansionBroader approvals and a long-term Tokyo-172 BCG supply agreement materially strengthen market access and supply reliability. These structural moves reduce commercialization friction, address chronic BCG shortages, and expand addressable markets—improving durable uptake potential and strategic positioning in bladder and other oncology indications.
Bears Say
Very Large Net LossesNearly $1B in trailing losses and sustained negative equity reflect entrenched operating deficits that impair financial flexibility. Over the medium term, persistent large losses raise the risk of asset write-downs, constrict strategic choices, and necessitate meaningful corrective profitability or continued external capital to sustain operations.
Persistent Negative Cash FlowConsistent negative operating and free cash flow indicate the business does not self-fund its commercial and R&D activities. Continued cash burn constrains reinvestment flexibility, increases dependence on financing, and can force trade-offs between commercialization, late‑stage trials, and margin improvement strategies over the coming months.
Financing / Dilution RiskDespite lower reported debt, negative equity and ongoing burn create structural reliance on external capital. This elevates the probability of equity issuance, asset sales, or dilutive financings, which can materially affect shareholder value and limit strategic options if capital markets tighten over the medium term.
ImmunityBio News
IBRX FAQ
What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was $1.95 and its highest was $12.43 in the past 12 months.
What is ImmunityBio’s market cap?
ImmunityBio’s market cap is $8.10B.
When is ImmunityBio’s upcoming earnings report date?
ImmunityBio’s upcoming earnings report date is Nov 05, 2026 which is in 86 days.
How were ImmunityBio’s earnings last quarter?
ImmunityBio released its earnings results on Aug 04, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.08 by -$0.14.
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Undervalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate is -0.07.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 1,059,836,300 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
ImmunityBio reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.08. Following the earnings report the stock price went down -2.797%.
Which hedge fund is a major shareholder of ImmunityBio?
Currently, no hedge funds are holding shares in IBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ImmunityBio Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.00 (83.10% Upside)
$13.00 (83.10% Upside)
Blogger Sentiment
Bullish
IBRX Sentiment 96%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Increased
By 133.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
135.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
112.88%
Trailing 12-Months
Company Description
ImmunityBio
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
IBRX Stock 12 Month Forecast
Average Price Target
$13.00
▲(83.10% Upside)
Technical Analysis
Ownership Overview
62.16% Insiders
4.06% Mutual Funds
1.00% Other Institutional Investors
25.58% Public Companies and Individual Investors